ethyl 9-hydroxy-1,3,4,6,7,9a-hexahydro-2H-quinolizine-8-carboxylate | 907188-81-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物
• 英文名称: ethyl 9-hydroxy-1,3,4,6,7,9a-hexahydro-2H-quinolizine-8-carboxylate
• 英文别名: ethyl 1-hydroxy-4,6,7,8,9,9a-hexahydro-3H-quinolizine-2-carboxylate
• CAS: 907188-81-2
• 化学式: C₁₂H₁₉NO₃
• 分子量: 225.288
• InChiKey: YIZHWHOOMCRGBC-UHFFFAOYSA-N

物化性质

• 沸点：
  349.4±42.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 9-hydroxy-1,3,4,6,7,9a-hexahydro-2H-quinolizine-8-carboxylate 在 盐酸 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 1a-Hydroxy-chinolizidin
  参考文献：
  名称：

  A concise synthesis of (±) and a total synthesis of (+)-epiquinamide

  摘要：

  A total synthesis of the quinolizidine alkaloid (+)-epiquinamide 1 has been achieved starting from (-)-pipecolinic acid 3. The key step is the highly diastereoselective addition of a TBDMS-protected propargyl alcohol to a chiral aldehyde derived from 3 to give erythro alkynol 19, which is then easily transformed into the desired bicyclic skeleton. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.05.092
• 作为产物：
  描述：

  ethyl 1-(4-ethoxy-4-oxobutyl)piperidine-2-carboxylate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以95%的产率得到ethyl 9-hydroxy-1,3,4,6,7,9a-hexahydro-2H-quinolizine-8-carboxylate
  参考文献：
  名称：

  A concise synthesis of (±) and a total synthesis of (+)-epiquinamide

  摘要：

  A total synthesis of the quinolizidine alkaloid (+)-epiquinamide 1 has been achieved starting from (-)-pipecolinic acid 3. The key step is the highly diastereoselective addition of a TBDMS-protected propargyl alcohol to a chiral aldehyde derived from 3 to give erythro alkynol 19, which is then easily transformed into the desired bicyclic skeleton. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.05.092

文献信息

• Thienopyridine inhibitors of RIPK2
  申请人：Celgene Corporation

  公开号：US11168093B2

  公开（公告）日：2021-11-09

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物及其使用方法。
• WO2020132384A5
  申请人：——

  公开号：WO2020132384A5

  公开（公告）日：2022-12-27
• THIENOPYRIDINE INHIBITORS OF RIPK2
  申请人：CELGENE CORPORATION

  公开号：EP3897630A1

  公开（公告）日：2021-10-27
• [EN] THIENOPYRIDINE INHIBITORS OF RIPK2<br/>[FR] INHIBITEURS THIÉNOPYRIDINE DE RIPK2
  申请人：CELGENE CORP

  公开号：WO2020132384A1

  公开（公告）日：2020-06-25

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. The present application provides technologies useful for inhibiting RIPK2. In some embodiments, provided technologies are useful for, among other things, treating and/or preventing inflammatory disorders such as inflammatory bowel disease. Among other things, the present application provides compositions comprising a compound reported herein (e.g., a compound of formula I, I', II, ΙI', III, III', IV, and/or IV'), or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.